inclusion criteria: patients with signs and symptoms corresponding to covid-19 viral infection and: admitted to hospital and who have been initiated with bsc treatment with mild to moderate disease as defined by the national institutes of health (nih) treatment guidelines confirmation of covid-19 infection this will be assessed by secondary laboratory confirmation of sars-cov-2 infection by reverse-transcription polymerase chain reaction (rt-pcr) or comparable methodology used by the hospital from any diagnostic sampling - source for analysis and recovery males and females between 18 and 75 years of age, inclusive female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) double-barrier method intrauterine devices non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) vasectomy of partner at least 6 months prior to screening willingness to complete assessments, questionnaires and records associated with the study provided voluntary, written, informed consent to participate in the study

inclusion criteria: patients with signs and symptoms corresponding to covid-19 viral infection and: admitted to hospital and who have been initiated with bsc treatment with mild to moderate disease as defined by the national institutes of health (nih) treatment guidelines confirmation of covid-19 infection this will be assessed by secondary laboratory confirmation of sars-cov-2 infection by reverse-transcription polymerase chain reaction (rt-pcr) or comparable methodology used by the hospital from any diagnostic sampling - source for analysis and recovery males and females between 18 and 75 years of age, inclusive female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) double-barrier method intrauterine devices non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) vasectomy of partner at least 6 months prior to screening willingness to complete assessments, questionnaires and records associated with the study provided voluntary, written, informed consent to participate in the study

inclusion criteria: 1. patients with signs and symptoms corresponding to covid-19 viral infection and: 2. admitted to hospital and who have been initiated with bsc treatment with mild to moderate disease as defined by the national institutes of health (nih) treatment guidelines 3. confirmation of covid-19 infection this will be assessed by secondary laboratory confirmation of sars-cov-2 infection by reverse-transcription polymerase chain reaction (rt-pcr) or comparable methodology used by the hospital from any diagnostic sampling - source for analysis and recovery 4. males and females between 18 and 75 years of age, inclusive 5. female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: - hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) - double-barrier method - intrauterine devices - non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - vasectomy of partner at least 6 months prior to screening 6. willingness to complete assessments, questionnaires and records associated with the study 7. provided voluntary, written, informed consent to participate in the study

inclusion criteria: 1. patients with signs and symptoms corresponding to covid-19 viral infection and: 2. admitted to hospital and who have been initiated with bsc treatment with mild to moderate disease as defined by the national institutes of health (nih) treatment guidelines 3. confirmation of covid-19 infection this will be assessed by secondary laboratory confirmation of sars-cov-2 infection by reverse-transcription polymerase chain reaction (rt-pcr) or comparable methodology used by the hospital from any diagnostic sampling - source for analysis and recovery 4. males and females between 18 and 75 years of age, inclusive 5. female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: - hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) - double-barrier method - intrauterine devices - non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - vasectomy of partner at least 6 months prior to screening 6. willingness to complete assessments, questionnaires and records associated with the study 7. provided voluntary, written, informed consent to participate in the study

inclusion criteria: 1. patients with signs and symptoms corresponding to covid-19 viral infection and: 2. not eligible for hospital admittance and are following the guidance from public health with mild to moderate disease as defined by the nih treatment guidelines 3. confirmation of covid-19 infection - this will be assessed by confirming virological diagnosis of sars-cov-2 infection (pcr) 4. males and females between 18 and 75 years of age, inclusive 5. absolute neutrophil count (anc) ≥ 0.6 ×109 cells/l 6. female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: - hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) - double-barrier method - intrauterine devices - non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - vasectomy of partner at least 6 months prior to screening 7. willingness to complete assessments, questionnaires and records associated with the study 8. provided voluntary, written, informed consent to participate in the study

inclusion criteria: 1. patients with signs and symptoms corresponding to covid-19 viral infection and: 2. not eligible for hospital admittance and are following the guidance from public health with mild to moderate disease as defined by the nih treatment guidelines 3. confirmation of covid-19 infection - this will be assessed by confirming virological diagnosis of sars-cov-2 infection (pcr) 4. males and females between 18 and 75 years of age, inclusive 5. absolute neutrophil count (anc) ≥ 0.6 ×109 cells/l 6. female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: - hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) - double-barrier method - intrauterine devices - non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - vasectomy of partner at least 6 months prior to screening 7. willingness to complete assessments, questionnaires and records associated with the study 8. provided voluntary, written, informed consent to participate in the study

inclusion criteria: 1. former smoker, defined as anyone who has stopped smoking for 3 months prior to enrollment and who had smoked at least 100 cigarettes in their lifetime and/or patients with steroid-resistant asthma 2. patients with signs and symptoms corresponding to covid-19 viral infection admitted to hospital and who have been initiated with bsc treatment 3. secondary laboratory confirmation of covid-19 infection by reverse-transcription polymerase chain reaction (rt-pcr) or comparable methodology used by the hospital from any diagnostic sampling - source for analysis and recovery 4. mild to moderate disease (national early warning score of ≤ 6) 5. males and females between 18 and 75 years of age, inclusive 6. bmi between 18.5 to 34.9 kg/m2, inclusive 7. absolute neutrophil count (anc) ≥ 0.6 ×109 cells/l 8. female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: - hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) - double-barrier method - intrauterine devices - non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - vasectomy of partner at least 6 months prior to screening 9. willingness to complete assessments, questionnaires and records associated with the study 10. provided voluntary, written, informed consent to participate in the study.

inclusion criteria: 1. former smoker, defined as anyone who has stopped smoking for 3 months prior to enrollment and who had smoked at least 100 cigarettes in their lifetime and/or patients with steroid-resistant asthma 2. patients with signs and symptoms corresponding to covid-19 viral infection admitted to hospital and who have been initiated with bsc treatment 3. secondary laboratory confirmation of covid-19 infection by reverse-transcription polymerase chain reaction (rt-pcr) or comparable methodology used by the hospital from any diagnostic sampling - source for analysis and recovery 4. mild to moderate disease (national early warning score of ≤ 6) 5. males and females between 18 and 75 years of age, inclusive 6. bmi between 18.5 to 34.9 kg/m2, inclusive 7. absolute neutrophil count (anc) ≥ 0.6 ×109 cells/l 8. female patient is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening or, females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. all hormonal birth control must have been in use for a minimum of three months. acceptable methods of birth control include: - hormonal contraceptives including oral contraceptives, hormone birth control patch (ortho evra), vaginal contraceptive ring (nuvaring), injectable contraceptives (depo-provera, lunelle), or hormone implant (norplant system) - double-barrier method - intrauterine devices - non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - vasectomy of partner at least 6 months prior to screening 9. willingness to complete assessments, questionnaires and records associated with the study 10. provided voluntary, written, informed consent to participate in the study.